SCHEMBL951307

SCHEMBL951307

C=CCc1ccc(OC(=O)CCCCCCCCCCCCCCC)c(OC)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.64
PPARA Q07869 3/20 0.60
TOP2A P11388 1/20 0.60
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CYP3A4 P08684 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
ALOX15 P16050 1/20 0.58
ALDH1A1 P00352 2/20 0.57
PPARG P37231 1/20 0.57
PPARD Q03181 1/20 0.57
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
EPHX2 P34913 1/20 0.53
NPC1 O15118 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20739903 1.00 PTGS1 (0.64) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL20723797 1.00 PTGS1 (0.64) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL20723701 1.00 PTGS1 (0.64) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL20723822 1.00 PTGS1 (0.64) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL20723700 0.99 PTGS1 (0.66) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL11613528 0.95 PTGS1 (0.67) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL9309996 0.94 PTGS1 (0.58) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL20739828 0.94 PTGS1 (0.58) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL31518883 0.94 ALOX15 (0.66) PTGS1PPARATOP2AMEN1KMT2A
SCHEMBL20723823 0.90 PTGS1 (0.64) PTGS1PPARATOP2AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019030643-A1 COMPOSITIONS OF EUGENOL DERIVATIVES FOR TREATMENT OF VISCERAL LEISHMANIASIS FOUNDATION FOR NEGLECTED DISEASE RESEARCH (IN) 2019-02-14 WO disclosed
EP-2280051-B1 Secondary emulsifiers for inverted emulsion fluids and methods for making an using same CLEARWATER INT LLC (US) 2015-02-11 EP disclosed
US-8821908-B2 Mold-resistant construction materials HENKEL AG & CO. KGAA (DE) 2014-09-02 US disclosed
EP-2280051-A1 Secondary emulsifiers for inverted emulsion fluids and methods for making an using same Clearwater International LLC (US) 2011-02-02 EP disclosed
US-20110021385-A1 SECONDARY EMULSIFIERS FOR INVERTED EMULSION FLUIDS AND METHODS FOR MAKING AND USING SAME CLEARWATER INTERNATIONAL, LLC (US) 2011-01-27 US disclosed
US-20110021385-A1 SECONDARY EMULSIFIERS FOR INVERTED EMULSION FLUIDS AND METHODS FOR MAKING AND USING SAME CLEARWATER INTERNATIONAL, LLC (US) 2011-01-27 US disclosed
US-7557145-B2 Inhibition of the asexual reproduction of fungi by eugenol and/or derivatives thereof HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2009-07-07 US disclosed
US-20070224250-A1 MOLD-RESISTANT CONSTRUCTION MATERIALS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2007-09-27 US disclosed
US-20060128813-A1 Inhibition of the asexual reproduction of fungi by eugenol and/or derivatives thereof HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070224250-A1 MOLD-RESISTANT CONSTRUCTION MATERIALS ERG28, DCXR, MGAM PTGS1 1285/4885PPARA 4563/4885TOP2A 1270/4885
US-20060128813-A1 Inhibition of the asexual reproduction of fungi by eugenol and/or derivatives thereof ERG28, MEP1A, ETF1 PTGS1 2316/4885PPARA 3408/4885TOP2A 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.